Araris is transforming the field of antibody-drug conjugates (ADCs), a next-generation cancer therapy that delivers potent drugs directly to tumors while minimizing damage to healthy tissue.

The company’s proprietary AraLinQ linker technology enables precise, stable, and site-specific drug attachment to antibodies, enhancing tumor targeting, reducing side effects, and streamlining manufacturing for scalable production.